Docetaxel Plus Oxaliplatin with 5-Fluorouracil May Be Effective for Advanced Gastric Cancer
the Cancer Therapy Advisor take:
According to a new study published in the journal Annals of Oncology, researchers have found that the combination of docetaxel, oxaliplatin, and 5-fluorouracil (TEF) may be effective alone or as a backbone regimen for newly developed targeted agents for the treatment of patients with advanced gastric cancer.
For this phase 2 study, researchers sought to evaluate docetaxel/oxaliplatin (TE), docetaxel/oxaliplatin/capecitabine (TEX), and TEF in patients with metastatic or locally recurrent gastric adenocarcinoma. Researchers randomly assigned 248 patients with advanced gastric cancer 1:1:1 to TE, TEF, or TEX.
Results showed a median progression survival of 7.66 months (95% CI: 6.97 - 9.40) for TEF, 4.50 months (95% CI: 3.68 - 5.32) for TE, and 5.55 months (95% CI: 4.30 - 6.37) for TEX. Median overall survival was 14.59 months (95% CI: 11.70 - 21.78) for TEF, 8.97 months (95% CI: 7.79 - 10.87) for TE, and 11.30 months (95% CI: 8.08 - 14.03) for TEX.
Tumor response rate for TEF was nearly double that of TE and TEX. Adverse effects were similar across all arms. The researchers suggest that TEF should be studied in phase 3 trials for patients with advanced gastric cancer alone or with targeted therapy.
Docetaxel, oxaliplatin, and TEF may be effective for the treatment of patients with advanced gastric cancer.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Considerations for Relapsed Myeloma Should Match Patient, Disease, and Therapy
- Triclosan and Cancer Risk: Is There a Link?
- Research Advances for Mutant KRAS-Driven Lung Adenocarcinoma
- Chemotherapy May Improve Survival Outcomes in High-Risk Soft-Tissue Sarcoma
- Aggressive Follow-Up Imaging in Breast Cancer Is Geography-Specific
- FDA Approves Ivosidenib for IDH1-Mutated Relapsed/Refractory Acute Myeloid Leukemia
- Clinical Stage at First Response May Predict Outcomes in Chronic Lymphocytic Leukemia
- Exercise and Cancer
- Increased Body Mass Index May Be Predictive of Recurrence, Progression in Bladder Cancer
- Aspirin, Non-Aspirin NSAID-Use May Improve Survival Outcomes in Ovarian Cancer